Juan M Tiraboschi
Overview
Explore the profile of Juan M Tiraboschi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, et al.
J Antimicrob Chemother
. 2024 Mar;
79(5):1133-1141.
PMID: 38546974
Introduction: The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48 weeks...
2.
Tiraboschi J, Rojas J, Zetterberg H, Blennow K, Niubo J, Gostner J, et al.
J Infect Dis
. 2020 Oct;
223(11):1928-1933.
PMID: 33049035
A major concern of human immunodeficiency virus (HIV) dual therapy is a potentially lower efficacy in viral reservoirs, especially in the central nervous system (CNS). We evaluated HIV RNA, neuronal...
3.
Imaz A, Tiraboschi J, Niubo J, Martinez-Picado J, Cottrell M, Domingo P, et al.
Clin Infect Dis
. 2020 Sep;
73(7):e1991-e1999.
PMID: 32945851
Background: The pharmacokinetics of bictegravir (BIC) and its association with the decay of human immunodeficiency virus (HIV)-1 RNA in genital fluids and the rectum have not yet been addressed. Methods:...
4.
Imaz A, Niubo J, Cottrell M, Perez E, Kashuba A, Tiraboschi J, et al.
Clin Infect Dis
. 2018 Dec;
69(8):1403-1409.
PMID: 30561517
Background: This study assessed the penetration and efficacy of tenofovir alafenamide (TAF) in the male genital tract (MGT) and the semen quality of individuals infected with human immunodeficiency virus (HIV)-1...
5.
Imaz A, Niubo J, Amara A, Khoo S, Ferrer E, Tiraboschi J, et al.
J Neurovirol
. 2018 Mar;
24(4):391-397.
PMID: 29542028
This study aimed to assess cerebrospinal fluid (CSF) drug concentrations and viral suppression in HIV-1-infected patients on ritonavir-boosted atazanavir (ATV/r) plus lamivudine (3TC) dual therapy. HIV-1-infected adults with suppressed plasma...
6.
Saumoy M, Tiraboschi J, Ordonez-Llanos J, Ribera E, Domingo P, Mallolas J, et al.
HIV Clin Trials
. 2017 Jan;
18(2):49-53.
PMID: 28081673
Background: The objective of this study was to determine the impact of tenofovir or abacavir discontinuation on low-density lipoprotein (LDL) phenotype and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in HIV-infected patients...
7.
Fox J, Tiraboschi J, Herrera C, Else L, Egan D, Dickinson L, et al.
J Acquir Immune Defic Syndr
. 2016 Oct;
73(3):252-257.
PMID: 27727157
To investigate the pharmacokinetics/pharmacodynamics of single-dose maraviroc 300 mg in HIV-1 exposure compartments. Maraviroc concentrations in blood, secretions (vaginal, urethral, oral, and rectal), and tissue (vaginal and rectal) were measured,...
8.
Tiraboschi J, Knobel H, Imaz A, Villar J, Ferrer E, Saumoy M, et al.
Antivir Ther
. 2015 Dec;
21(4):359-63.
PMID: 26656921
Background: Lopinavir/ritonavir (LPV/r) monotherapy is used in selected virologically suppressed HIV-infected patients. Some would prefer a once-daily (OD) dose instead of the usual twice-daily dose to favour adherence. However, trough...
9.
Hamzah L, Tiraboschi J, Iveson H, Toby M, Mant C, Cason J, et al.
Antivir Ther
. 2015 Oct;
21(4):287-96.
PMID: 26460504
Background: Efavirenz (EFV) has been associated with reductions in vitamin D (25[OH]D) and tenofovir (TDF) with increased bone turnover, reductions in bone mineral density (BMD) and renal tubular dysfunction. We...
10.
Di Yacovo M, Molto J, Ferrer E, Curran A, Else L, Gisslen M, et al.
J Antimicrob Chemother
. 2015 Jan;
70(5):1513-6.
PMID: 25608583
Objectives: The objective of this study was to assess whether a lower dose than the currently used one of darunavir/ritonavir might achieve good CSF concentrations and contribute to inhibition of...